This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The lack of collaboration between biologists, chemists, engineers and data scientists represents a significant barrier. He holds a master’s degree from University of Salerno in political sciences and marketing. Compartmentalised teams struggle to fully leverage multimodality, leading to suboptimal solutions.
Real technology spend includes observability tools, containers, data platforms, SaaS licensing, AI/ML, and peripheral services, sometimes hand-waved away as shadow IT or just life as part of an unavoidable cost center. Are Finance, Product, and Engineering collaborating on goals, reporting, and forecasting?
Its applications include studying disease pathology to develop targeted therapeutics, visualising enzymes that can decompose plastics, and engineering solutions to antibiotic resistance, among many others. Further, trade secrets offer no protection against independent discovery or reverse engineering by competitors.
The antibiotic market has long faced significant barriers to innovation, with structural issues that make it difficult for new antibiotics to gain traction. As the demand for novel antibiotics remains limited due to the preference for cheaper generics, the market has struggled to incentivise much-needed breakthroughs.
Unlike earlier attempts to inhibit individual mutations such as KRAS G12C, daraxonrasib is engineered to have broader inhibitory activity across multiple RAS mutations. This aligns both parties’ interests toward long-term success in the market.
Published July 18, 2025 • Updated 3 hours ago Ned Pagliarulo Lead Editor post share post print email license The U.S. Alamy The Food and Drug Administration will ask Sarepta Therapeutics to halt all shipments of its marketed gene therapy for Duchenne muscular dystrophy, a source familiar with the matter confirmed to BioPharma Dive.
For years, the company was primarily known for licensing its C1 platform for the development of therapeutic biologics and vaccines. Our C1 and Dapibus™ production platforms remain the engines we expect to drive commercial execution. The rebranding reflects our top priority: to deliver high-value input proteins at commercial scale.”
Published June 27, 2025 Ned Pagliarulo Lead Editor post share post print email license Bristol Myers Squibb sells two CAR-T cell therapies for cancer. Dive Insight: Since the FDA’s approval of Novartis’ Kymriah for leukemia in 2017, six more CAR-T therapies have reached market.
But Sensei’s true value isnt limited to content operations, it’s the unified AI engine that quietly powers marketing intelligence, customer personalization, and even creative automation across Adobes enterprise ecosystem. Forecast campaign outcomes and key metrics with predictive analytics.
a leading global provider of immuno-oncology imaging agents, today announced it has signed a new multi-year, non-exclusive license with Pfizer Inc. ImaginAb will receive license fees and payments for manufacturing and other support. LOS ANGELES , Jan. 7, 2021 /PRNewswire/ — ImaginAb Inc. , No other terms were disclosed.
Moving research from concept to market is like conducting a symphony — there are numerous players and stakeholders, each bringing their unique expertise to work in harmony and advance a project. If approved, the company can then market and distribute the therapeutic. How do BioDAOs differ from investment DAOs?
Ltd (“Juyou”), a biotechnology company that develops and sells medical and cosmetic skincare products, for the commercialization and development of Pliaglis ® in mainland China (the “License Agreement”).
million and US$1.8 For additional information, please visit [link].
Together, these attributes provide a strong foundation for protein expression with enough adaptability to produce much of the commercial and therapeutic protein market. For example, a CDMO with deep sequencing knowledge and a proprietary cell line will achieve significantly better performance than CDMOs that license third-party technologies.
But there’s one more type of training your healthcare content strategists and marketers need that you’re (probably) not doing: healthcare writing training. The skills that often are part of successful digital marketing in other areas of commerce don’t always translate exactly to healthcare marketing. And it’s not you.
Magento offers powerful marketing, search engine optimization, and Catalog management tools. Magento is a largely customizable E-Commerce platform available under both open-source and marketablelicenses. Salesforce is a popular CRM tool for support, deals, and marketing brigades worldwide. I hope it’s useful.
Ambulero holds an exclusive license from the University of Miami to develop and commercialize research from the laboratories of Drs. Ambulero’s cell therapy program uses stromal cells engineered to express E-selectin to promote tissue repair. As part of the investment, Ambulero and Orphinic formed a Polish subsidiary (Ambulero Sp.
Brent Fagg currently serves as Virginia Commonwealth University’s Senior Licensing Manager in their TechTransfer and Ventures unit. For instance, when engaging a private engineering firm, costs might be presented as $150/hour for a junior engineer. This ongoing dialogue provided a new opportunity for our partnership.
Anderson Professor of Chemical and Biomolecular Engineering, and his colleagues, are reporting in iScience the event of an intranasal subunit vaccine that gives durable local immunity against inhaled pathogens. The function of the adjuvant is to market the body’s immune reaction. But now, we’re one step closer.
To create a roadmap for research in this space, NIDA along with the National Center for Complementary and Integrative Health (NCCIH), the National Cancer Institute (NCI), and the Centers for Disease Control and Prevention (CDC), sponsored an independent consensus study by the National Academies of Sciences, Engineering, and Medicine (NASEM).
The Series B financing will be mainly used to conduct global clinical trials, research and development, and product in-licensing activities. To date, Inmagene has raised over $40 million financing. Inmagene is a leading drug development company focused on immunology-related therapeutic areas.
New test automation technologies are entering the market as the scope expands. The market was previously dominated by proprietary tools like selenium. However, new open-source tools are now leading the market. Playwright is one of many Test Automation Frameworks available in the market. What is Playwright? The Apache 2.0
All financial reports are released before market open CET. Innate Pharma’s commercial-stage product, Lumoxiti, in-licensed from AstraZeneca in the US, EU and Switzerland, was approved by the FDA in September 2018. .
September 15, 2021:
Publication of half year financial statements.
Taconic Biosciences is a fully-licensed, global leader in genetically engineered rodent models and services. Media Contact: Kelly Owen Grover
Director of Marketing Communications
518-478-6095
kelly.grover@taconic.com .
Source link.
The fully integrated pharmaceutical company creates value through China’s specialty pharmaceutical markets with focus on iron deficiency, pain management and respiratory. The engineered cells are protected by Sigilon’s Afibromer biomaterials matrix, which shields them from immune rejection and fibrosis. SciNeuro Pharmaceuticals .
OTC PINK:DECN) www.decisiondiagnostics.co , a leading manufacturer and worldwide distributor of diabetic test strips engineered to operate on legacy glucose meters through its subsidiary Pharma Tech Solutions, Inc., is the leading manufacturer and worldwide distributor of diabetic test strips engineered to operate on legacy glucose meters.
These mAbs are already of human origin and functionally optimized for high potency by the donor’s immune system; hence, they technically do not require genetic engineering or further optimization to achieve full functionality. AR-711 is an in-licensed mAb that is directed against the receptor binding domain of the SARS-Cov 2 virus.
Oldcastle Infrastructure Part of CRH (LSE: CRH, ISE: CRG, NYSE: CRH), a Fortune 500 company with $31B in revenue in 2021, Oldcastle Infrastructure is responsible for many of the engineering solutions—communications, transportation, energy, buildings, and water—that surround us every day.
iosBio , a UK-based biotechnology company, has announced an exclusive worldwide licensing agreement with ImmunityBio , a clinical-stage immunotherapy company, for rights to use iosBio’s OraPro vaccine platform technology to test the oral administration of ImmunityBio’s vaccine candidate. Download this exclusive report here.
Here are the top 7 reasons this should be the case: XM Cloud Empowers Marketers to Create their own Components and Get Started with Personalization XM Cloud provides a brand-new WYSIWYG component building experience to marketers, who can lay out their components however they want and use them directly in pages.
“Over the last five years, Teneobio developed leading-edge expertise in efficiently engineering differentiated multispecific and bispecific therapeutics for numerous indications with potentially better safety, efficacy and pharmacokinetic profiles than the first generation of T-cell engagers. chief executive officer of Teneobio.
It continues from drug candidate screening and selection, prototype generation, preclinical validation, early clinical studies, to later clinical studies and post-market monitoring. Efficient formulation processes can reduce development costs and time to market. Engineering precision nanoparticles for drug delivery. Haley, R.M.
To purchase DermSafe: Just search for “DermSafe” in Amazon.ca’s search engine or click on www.amazon.ca/shops/dermsafe. Ovation earns revenues from licensing and development fees, royalties, the sale of Invisicare to its licensees and now revenue from its own product sales. The product listing offered on Amazon.ca
Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA), under Priority Review, for Port Delivery System with ranibizumab (PDS) for the treatment of neovascular or “wet” age-related macular degeneration (nAMD). Roche (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S.
Their team is excited by the potential of AV1 support in the NVIDIA L4 GPU and, based on early testing, is seeing significant quality improvement and bandwidth reduction, with similar throughput as GPU HEVC transcoding,” said Jiayao Yu, engineering manager for Snap’s Media Delivery Platform.
It is also an off-the-shelf therapy, meaning that people do not have to wait for cell collection and genetic engineering before starting treatment, which could be particularly important for patients who are at a high-risk of their disease progressing. A final decision is expected from the European Commission (EC) in the near future.
We believe our allogenic CAR-T platform is significantly stronger with chPD1 target licensed from Longwood University. The pipeline development is leveraged through the Company’s proprietary target discovery engine called “DIAMOND.” Amorette Barber of Longwood University will be heading up our chPD1 program.
About the Innate-Sanofi agreement: The Company has a research collaboration and licensing agreement with Sanofi to apply Innate’s proprietary technology to the development of innovative multispecific antibody formats engaging natural killer (NK) cells to kill tumor cells and secrete cytokines through the activating receptor NKp46.
Innate Pharma’s commercial-stage product, Lumoxiti, in-licensed from AstraZeneca in the US, EU and Switzerland, was approved by the FDA in September 2018. About Innate Pharma:
Innate Pharma S.A. Lumoxiti is a first-in class specialty oncology product for hairy cell leukemia.
The decrease in Adcirca revenues was driven by continued erosion of market share due to generic competition.
Sales and marketing.
License-related fees (5).
License-related fees (5).
Cost of product sales.
.
As explained in a 2013 Government Accountability Office report, the intent of the CPG was to “identify those circumstances under which the agency believed establishments with retail pharmacy licenses were engaged in ‘manufacturing, distributing, and promoting unapproved new drugs’ in a manner outside the traditional pharmacy practice of compounding.”
The intent is to create a single market for data, establish common European data spaces, and allow the companies that generate the data to keep control and maintain trade secrets. market regardless of the location of the business. The Act would apply to manufacturers of connected products and related services on the E.U.
Boehringer Ingelheim and the Agency for Science, Technology and Research (A*STAR) today announced a global licensing agreement under which Boehringer Ingelheim will obtain exclusive worldwide rights to research, develop and commercialize products based on a panel of innovative, tumor-specific antibodies from A*STAR. star.edu.sg.
But that number doesn’t quite reflect the company’s likely market valuation , which is expected to be between $9 billion and $12 billion. Based in Seattle, Washington, Sana focuses on in vivo and ex vivo cell engineering platforms to develop therapies for cancer, diabetes, cardiovascular disease, CNS disorders, and genetic diseases.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content